This publication has been discontinued on July 19, 2011.
Abstract
Limited Efficacy of Conventional Therapies Kindle Interest in Antibody Technology
The limited efficacy of conventional therapies, especially in the case of
several autoimmune and inflammatory disorders, is creating a strong demand for
safe and effective alternate treatments. Considering this, monoclonal
antibodies (Mabs) are expected to play a crucial role in facilitating the
treatment of not only autoimmune and inflammatory disorders, but also
cardiovascular and other infectious diseases. Crucially, in furthering
research and overcoming challenges related to the humanization of antibodies
of murine origin, technology developers have successfully developed several
antibody humanization techniques. These techniques remove the immunogenicity
of the murine antibody in humans, thereby solving the problem of human
anti-mouse antibodies (HAMA) response.
This Technical Insight study provides insights into developments in antibody
technology. It identifies and analyzes emerging technologies and novel
applications of existing ones in the context of antibody technology
developments. Also, the study endeavors to cover advances in R&D, product
development, and the regulatory aspects related to applications of antibodies.
Being a global study, the research service has been categorized into findings
that fall within the North American, European, and Asia Pacific regions.
Increasing Elderly Population Drives Demand for Immunotherapies
The expected increase in elderly population in industrial nations over the
next two decades is likely to be the most important factor driving the demand
for immunotherapies. While other autoimmune disorders and age-related
illnesses such as arthritis, Alzheimer's, as well as Parkinson's are equally
affecting the quality of life, the mortality from cancer, diabetes, liver, and
kidney diseases still remains high. Considering this, cancer, which has been
poorly served by traditional chemotherapies, represents a major area of
opportunity for biotech firms to develop immunotherapeutic products.
Among the many advances in antibody technologies, scientists at Jefferson
Medical College have used tobacco plants to produce Mabs - tiny guided protein
missiles that can target and hunt down cancer cells. The plants promise to
provide a cheaper, faster method of producing anticancer antibodies, raising
hopes that the technology can one day be used in humans. "Similarly, the Dutch
biotechnology firm Crucell N.V recently announced the discovery of a
monoclonal antibody against the West Nile virus, which causes a fatal form of
encephalitis in humans," says the analyst of this research service. "The
company expects that this antibody may provide a route to prophylaxis,
providing passive immunity in the event of an outbreak and, possibly, therapy
for patients who might otherwise develop encephalitis."
Table of Contents
1 EXECUTIVE SUMMARY
- Introduction
- Introduction to Antibodies
- Overview of Antibody Industry
- Scope and Methodology
- Scope and Segmentation of the Research Service
- Methodology
2 ANTIBODY TECHNOLOGY OVERVIEW
- Technology Primer
- Monoclonal Versus Polyclonal Antibodies
- Applications
- Innovations in Key Companies and Universities
- Emerging Technology Innovations in Companies
- Emerging Technology Innovations in Universities
3 TECHNOLOGY ADOPTION FACTOR ANALYSIS
- Technology Analysis
- Restraints
- Challenges
- Drivers
- Influential Market Factors
- Corporate Collaborations
- Funding Sources
4 INNOVATIVE DEVELOPMENTS IN ANTIBODY TECHNOLOGIES IN NORTH AMERICA
- Companies
- Fully Human Proteins from Modified Yeast
- New Monoclonal Antibody Delivery and Synthesis Technology
- Novel Antibodies for Effective Antimicrobial Therapy
- Novel Technology Platforms for Making Monoclonal Antibodies for Cancer
and Immunological Diseases
- Monoclonal Antibodies for Cancer and Inflammatory Diseases
- Transgenic Mice for Production of Fully Human Antibodies
- Antigen Based Therapeutic Synthetic Vaccines
- Novel Human Antibodies against Cancer
- Unique Antibody Based Approach for Disease Diagnosis and Management
- Therapeutic Antibodies for Inflammatory and Immunological Diseases
- Novel Antibody Array to Study Cytokine Expression Levels
- Simple Low Cost Assay for Studying Gene-Protein Interactions
- Innovative Technology for Generation of Cancer Therapeutics
- Monoclonal Antibodies for Inflammatory Diseases
- Academic Institutions
- Antibodies as a Cure for Anthrax
- Stress Increases Antibody Production in Hybridoma Cells Grown in Culture
5 INNOVATIVE DEVELOPMENTS IN ANTIBODY TECHNOLOGIES IN EUROPE
- Companies
- Production of Fully Human Antibodies through Human Combinatorial
Antibody Libraries
- Novel Technology Targets Bacterial Haptens
- An Alternative Therapy for Malaria - Antimalarial Antibodies
- Antibodies against West Nile Virus
- Therapeutic Monoclonal Antibodies through Phage Display Libraries
- Antibody Production through Genetic Immunization Technique
- Academic Institutions
- The CAMPATH Series of Antibodies
- Antibodies for Malarial Parasite
6 INNOVATIVE DEVELOPMENTS IN ANTIBODY TECHNOLOGIES IN APAC
- Companies
- Unique Humanization Technology for Producing Antibody Products
- Innovative Technology for Producing High Affinity Monoclonal Antibodies
- Small Molecule Cytokine Antagonists as Therapy for Inflammatory Disorders
- Immunomodulatory Drug as a Treatment for Autoimmune and Inflammatory
Disorders
- Academic Institutions
- Research for Treatment of Miscarriage
- Study Shows Evidence of Link between a Common Virus and Breast Cancer
7 PATENTS AND KEY CONTACTS
8 FROST & SULLIVAN 2005 SCIENCE AND TECHNOLOGY AWARDS
- Excellence in Technology Award
- Award Description
- Award Recipient
- Technology Innovation Award
- Award Description
- Award Recipient
- Excellence in Research Award
- Award Description
- Award Recipient
9 CRITICAL REFERENCE TABLES
- Decision Support Databases
- Number of Biotech Companies (1999 to 2006)
- Private Funding for Research in Biotechnology (1999 to 2006)
- Government Funding for Research in Biotechnology (1999 to 2006)
- Incidence of HIV and AIDS (1999 to 2006)
- Breast Cancer Incidence (1999 to 2006)
- Lung Cancer Incidence (1999 to 2006)
- Prostate Cancer Incidence (1999 to 2006)
- Prevalence of Alzheimer's Disease (1999 to 2006)
- Prevalence of Multiple Sclerosis (1999 to 2006)
